Dual-Targeting Neuroendocrine Tumor Composition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for neuroendocrine tumors, such as neuroblastoma, paraganglioma, and pheochromocytoma, using meta-iodobenzylguanidine (MIBG) and alpha-v-beta-3 integrin antagonists have limited efficacy in suppressing tumor growth and viability, with maximum uptake and suppression ranging from 40-50%, necessitating the development of a more effective dual targeting approach.
Innovation Solution
A composition comprising N-benzyl guanidine connected via a linker to a thyrointegrin αvβ3 receptor antagonist, forming a single chemical entity that targets both the norepinephrine transporter and the integrin αvβ3 receptor, utilizing a polymer linker like Polyethylene Glycol (PEG) to enhance uptake and suppression efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If separate treatments with norepinephrine transporter targets (e.g., MIBG) and thyrointegrin antagonists are used, then tumor targeting is achieved, but suppression efficacy is limited to 40-50%
Solution Approach 1:
The patent combines N-benzyl guanidine (norepinephrine transporter target) and thyrointegrin αvβ3 receptor antagonist into a single dual-targeting compound connected by a linker. This merging of two separate therapeutic agents into one molecule enables simultaneous targeting of both the norepinephrine transporter and integrin αvβ3 receptor, achieving 80-100% tumor suppression efficacy compared to 40-50% with separate treatments.
Solution Approach 2:
The invention creates a composite molecular structure that integrates two distinct pharmacophores (N-benzyl guanidine and thyrointegrin antagonist) into a single compound. This composite approach allows the molecule to exhibit dual functionality: targeting norepinephrine transporter for uptake and binding integrin αvβ3 receptor for enhanced tumor suppression, thereby resolving the efficacy limitation of single-target therapies.
2Productivity
If dual targeting composition is used, then tumor suppression efficacy increases to 80-100%, but the composition structure becomes more complex
Solution Approach 1:
The dual-targeting compound is segmented into distinct functional modules: the N-benzyl guanidine moiety for norepinephrine transporter recognition, the linker for structural connection, and the thyrointegrin antagonist moiety for integrin receptor binding. This segmentation allows each component to perform its specific function while maintaining overall molecular stability and biological activity.
3Reliability
If MIBG is used for neuroendocrine tumor treatment, then norepinephrine transporter targeting is achieved, but tumor growth suppression remains sub-optimal
Solution Approach 1:
The patent creates a multi-functional compound that performs multiple therapeutic roles simultaneously: (1) targets norepinephrine transporter for cellular uptake, (2) binds integrin αvβ3 receptor to inhibit tumor growth and angiogenesis, and (3) provides synergistic therapeutic effect. This multi-functionality overcomes the single-target limitation of MIBG and achieves superior tumor growth suppression.
Data Source
Figure 1
Figure 2a
Figure 2b
AI summary
Chemical compositions and methods of synthesis thereof. The compositions disclosed and described herein are directed toward thyroid hormone ανβ3 integrin receptor antagonists conjugated to targets of the norepinephrine transporter (NET) or the catecholamine transporter. The compositions have a dual targeting effect and increased targeting efficiency in the treatment and diagnostic imaging of neuroendocrine tumors.